Editorial
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Jan 15, 2025; 16(1): 98804
Published online Jan 15, 2025. doi: 10.4239/wjd.v16.i1.98804
Prediabetes and atrial fibrillation risk stratification, phenotyping, and possible reversal to normoglycemia
Hyder O Mirghani
Hyder O Mirghani, Department of Internal Medicine, University of Tabuk, Tabuk 51941, Tabuk, Saudi Arabia
Author contributions: Mirghani HO conceptualized and designed the study, the literature search, the drafting, and critical revision, and provided the final approval of the version to be published.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hyder O Mirghani, DM, Professor, Department of Internal Medicine, University of Tabuk, Prince Fahd Bin Sultan, Tabuk 51941, Tabuk, Saudi Arabia. s.hyder63@hotmail.com
Received: July 6, 2024
Revised: October 19, 2024
Accepted: November 5, 2024
Published online: January 15, 2025
Processing time: 146 Days and 23.4 Hours
Core Tip

Core Tip: Patients admitted with prediabetes and atrial fibrillation are at high risk of major adverse cardiac or cerebrovascular events independent of confounding variables, as shown by Desai et al. The shared pathophysiology between the three serious and common diseases establish a vicious circle, culminating in high atherogenicity. In another study, Batta and Hatwal raised important points regarding risk stratification, timeline the role of metformin use among patients with prediabetes, and the impact of reversion of prediabetes to normoglycemia on major adverse cardiac or cerebrovascular events. We congratulate Desai et al for their valuable results and Batta and Hatwal for their insights and future directions. We believe and support the above. However, the studies approached inpatients retrospectively. Another important issue that can influence diabetes outcomes is stress hyperglycemia. Here, we give broader insight into proper interventions to reduce the risk of major adverse cardiac or cerebrovascular events in particular glucagon-like peptide-1 agonists, sodium-glucose cotransporters-2 inhibitors, and bariatric surgery.